ODI Pharma AB announced Group earnings results for the third quarter and nine months ended March 31, 2021. For the quarter, the Group's net sales amounted to SEK 0 against SEK 1,567 a year ago. The Group's loss after financial items amounted to SEK 41,280 against SEK 1,662,333 a year ago. Loss per share amounted to SEK 0.0031 against SEK 0.11 a year ago. For the nine months, The Group's net sales amounted to SEK 0 against SEK 218,520 a year ago. The Group's loss after financial items amounted to SEK 2,081,166 against 3,712,338 a year ago. Loss per share amounted to SEK 0.14 against SEK 0.28 a year ago.